Table 1.

Study groups. Experimental conditions are detailed in the Materials and Methods section. Each experiment included 9 to 15 mice per group, which were sacrificed 11–15 weeks post AAV-HBV injection. At least 3 time points after TG 1050 administration were monitored for viral parameters. Mean HBsAg levels at baseline for each study group are shown (with standard deviation).

Experiment	N° of mice / group	TG1050 dose (vp/inj/mouse)	Days of TG1050 treatment	Data points post treatment	Analysis up to Day	Mean HBsAg level at baseline in ng/mL (Standard Deviation)
A	12	2E+9	32, 39, 46	5	88	19887 (12417)
	12	—	—			19495 (11857)
B	12	2E+9	34, 41, 48	3	80	37513 (31531)
	11	—	—			37518 (28100)
C	10	2E+9	32, 39, 46	5	98	34733 (15414)
	10	—	—			32441 (19730)
D	10	2E+9	32, 39, 46	5	98	23221 (14248)
	9	—	—			26013 (13089)
E	10	2E+9	40, 47, 54	3	81	51499 (51446)
	10	—	—			46540 (40588)
F	15	2E+9	36, 43, 50	3	76	40983 (26475)
	15	—	—			40876 (25911)
G	10	2E+9	36, 43, 50	5	104	28166 (21438)
	10	—	—			27078 (17751)